- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
A hepatitis B drug could be effective against premature aging diseases
Massive Science
The ends of our DNA, called telomeres, get shorter as we age. Our cells lose a bit of telomere every time they divide. This shortening is a normal and needed process that serves a protective function against cancer. This is because the older our cells get, the more likely they are to have accumulated damage or mutations that make them function incorrectly. Telomere shortening helps to take old cells that are reaching their “best before date” off the shelf before they can cause trouble.
But this can backfire: cells can shorten their telomeres too quickly, age rapidly, and die. This is what causes a subset of genetic premature aging diseases, including idiopathic pulmonary fibrosis, forms of aplastic anemia, and a rare disease called dyskeratosis congenita. Unfortunately, there are currently no available drug-based therapies for treating telomere-driven premature aging diseases.
Now, a candidate drug has found a new potential purpose in treating premature aging disease.
This drug, called RG7834, was originally identified as an inhibitor of hepatitis B virus (HBV). While it has been found to be well-tolerated in short-term administration to living organisms (like rodents and primates), this drug does not cure HBV, and is not yet publicly available. Interestingly, the host cell proteins affected by RG7834 are two enzymes that modify many different RNAs. These enzymes can cause degradation of host cell RNA — so RG7834 keeps RNA around that the cell otherwise might get rid of. |
|